☆ 4.7 Article

Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

EUROPEAN JOURNAL OF CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Paul DiSilvestro et al.

Summary: Maintenance therapy with olaparib showed sustained progression-free survival benefit in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. After a 7-year follow-up, there was a clinically meaningful improvement in overall survival. The incidence of myelodysplastic syndrome and acute myeloid leukemia was low.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Cancer statistics, 2023

Rebecca L. Siegel et al.

Summary: The American Cancer Society predicts that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. While incidence trends for most cancers are favorable, prostate cancer saw a significant increase of 3% annually from 2014 to 2019. However, the overall cancer death rate continues to decline due to advances in treatment, with a 33% reduction since 1991.

CA-A CANCER JOURNAL FOR CLINICIANS (2023)

Add to Collection

Article Oncology

Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer

Konstantin Weber-Lassalle et al.

Summary: Cancer patients, particularly those with ovarian cancer, have a high prevalence of blood-specific mutations in clonal hematopoiesis (CH)-associated genes, which may be influenced by genetic factors.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Add to Collection

Article Oncology

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ ENGOT-OV26/GOG-3012 study

Roisin E. O'Cearbhaill et al.

Summary: This study evaluates the association between surgical timing and postoperative residual disease status on the efficacy of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer at high risk of recurrence.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)

Bradley J. Monk et al.

Summary: This study evaluates the efficacy of rucaparib as a first-line maintenance treatment in ovarian cancer patients, showing significant benefits of rucaparib compared to placebo in patients with and without HRD.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Obstetrics & Gynecology

Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)

Ning Li et al.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update

William P. Tew et al.

Summary: ASCO Rapid Recommendations Updates provide revisions to select ASCO guideline recommendations based on new and practice-changing data. The goal is to disseminate updated recommendations in a timely manner to inform health practitioners and the public on the best available cancer care options.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Letter Oncology

Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines

N. Colombo et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib

Tanya T. Kwan et al.

Summary: The study suggests that preexisting TP53 CHIP variants may be associated with the development of t-MNs after rucaparib treatment, indicating a potential genetic role in t-MNs development.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andres Poveda et al.

Summary: Olaparib provided a median overall survival benefit of 12.9 months compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Although statistical significance was not reached, these findings are arguably clinically meaningful and support the use of maintenance olaparib in these patients.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

N. Colombo et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

A. Gonzalez-Martin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Oncology

Exploring and comparing adverse events between PARP inhibitors

Christopher J. LaFargue et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

K. Moore et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Eric Pujade-Lauraine et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

M. R. Mirza et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Multidisciplinary Sciences

Management of relapsed ovarian cancer: a review

Gonzalo H. Giornelli

SPRINGERPLUS (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.